Alnylam Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$164.80

+3.07%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:55 IST · A quote does not mean the product is available to trade on your account.

Day's open: $166.73
Previous close: $159.89
Volume: 3.6M
Day's high: $170.49
Day's low: $160.29

In brief

Alnylam Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $22.07B.
Its shares closed at $159.89 on 3 Nov 2026, down 63.2% over the past year.
From India you can buy ALNY in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alnylam Pharmaceuticals, Inc. (ALNY) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ALNY share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ALNY options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

2.5% above its 52-week low
Closed at $159.89 on 3 Nov 2026: 66.7% below the 52-week high of $479.79 (3 Dec 2025) and 2.5% above the low of $156.00 (2 Nov 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Behind SPY over 1 year
1 month: −27.3% (SPY −2.6%). 3 months: −27.0% (SPY −2.2%). 1 year: −63.2% (SPY +10.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALNY, SPY · as of 3 Nov 2026
5.1 days to cover short interest
6.6M shares were sold short at the 15 Oct 2026 settlement, 4.9% of the 133.9M shares outstanding; covering them would take 5.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 3 Nov 2026 close of $159.89 was 31.5% below its 50-day average ($233.41) and 43.6% below its 200-day average ($283.48). It has closed below the 200-day for 205 sessions, since 12 Jan 2026. The 50-day average crossed below the 200-day on 11 Feb 2026, 183 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Volume 1.9× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 3.8M shares was 1.9× the average of the 30 sessions before it (2.0M), as the price rose 1.2%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month−27.3%

6 months−46.9%

1 year−63.2%

5 years−7.5%

Newswire

About

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Website

Notable moves

July 30, 2026
−28.31%
June 24, 2024
+34.52%
August 3, 2022
+49.33%

Newswire

About

Website

Notable moves

July 30, 2026
−28.31%
June 24, 2024
+34.52%
August 3, 2022
+49.33%

Alnylam Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$164.80

+3.07%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:55 IST · A quote does not mean the product is available to trade on your account.

Day's open: $166.73
Previous close: $159.89
Volume: 3.6M
Day's high: $170.49
Day's low: $160.29

In brief

Alnylam Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $22.07B.
Its shares closed at $159.89 on 3 Nov 2026, down 63.2% over the past year.
From India you can buy ALNY in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alnylam Pharmaceuticals, Inc. (ALNY) shares from India?

Do I need the price of a whole ALNY share to invest?

How much can I invest in US stocks in a year?

Can I trade ALNY options or futures?

Insights

Quotes run fifteen minutes behind.

2.5% above its 52-week low
Closed at $159.89 on 3 Nov 2026: 66.7% below the 52-week high of $479.79 (3 Dec 2025) and 2.5% above the low of $156.00 (2 Nov 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Behind SPY over 1 year
1 month: −27.3% (SPY −2.6%). 3 months: −27.0% (SPY −2.2%). 1 year: −63.2% (SPY +10.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALNY, SPY · as of 3 Nov 2026
5.1 days to cover short interest
6.6M shares were sold short at the 15 Oct 2026 settlement, 4.9% of the 133.9M shares outstanding; covering them would take 5.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 3 Nov 2026 close of $159.89 was 31.5% below its 50-day average ($233.41) and 43.6% below its 200-day average ($283.48). It has closed below the 200-day for 205 sessions, since 12 Jan 2026. The 50-day average crossed below the 200-day on 11 Feb 2026, 183 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Volume 1.9× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 3.8M shares was 1.9× the average of the 30 sessions before it (2.0M), as the price rose 1.2%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month−27.3%

6 months−46.9%

1 year−63.2%

5 years−7.5%

Newswire

About

Website

Notable moves

July 30, 2026
−28.31%
June 24, 2024
+34.52%
August 3, 2022
+49.33%

Newswire

About

Website

Notable moves

July 30, 2026
−28.31%
June 24, 2024
+34.52%
August 3, 2022
+49.33%

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. in brief

2.5% above its 52-week low

Behind SPY over 1 year

5.1 days to cover short interest

Below its 50- and 200-day averages

Volume 1.9× its 30-session average on 3 Nov 2026

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. in brief

2.5% above its 52-week low

Behind SPY over 1 year

5.1 days to cover short interest

Below its 50- and 200-day averages

Volume 1.9× its 30-session average on 3 Nov 2026